Semaglutide on TikTok: separating real results from hype

What did @titacrespocosmetic2 actually say?

Honestly? It's hard to tell. The transcript from this video is almost entirely incoherent. The creator references something about a product being difficult to get, mentions "providing a restaurant to everyone," and talks about not being able to "make a business like this." There is no clear, verifiable medical or factual claim being made in any conventional sense.

The hashtags tell us more than the words do. The video is tagged with #ozempic and #semaglutida, which places it firmly in the GLP-1 space. The #ventasonline hashtag, which translates to "online sales," is a significant red flag. Combined with #tutorial, it strongly suggests this video may be promoting or directing viewers toward purchasing semaglutide or a related product through unregulated online channels. That context matters a lot, even if the words themselves don't hang together.

We can't fact-check gibberish directly, but we can fact-check what this video appears to be doing and what the surrounding context implies.

Does the science back this up?

There is no coherent scientific claim in this video to evaluate. What we can address is the implied framing: that GLP-1 medications like semaglutide are hard to access, and that some alternative or workaround product is available for purchase online. On the access point, the creator is not entirely wrong, but the implied solution is dangerous.

Semaglutide shortages have been a real and documented problem. The FDA placed both Ozempic and Wegovy on its drug shortage list at various points between 2022 and 2024. Research published by Hernandez et al. (2024, JAMA Health Forum) confirmed that GLP-1 shortage-related disruptions were affecting millions of patients managing both type 2 diabetes and obesity. So the underlying frustration about access is grounded in reality.

However, the response to a drug shortage is not to source medications from unverified online vendors. The FDA has repeatedly warned that compounded semaglutide products sold online vary enormously in purity, concentration, and safety. There is no peer-reviewed evidence that unregulated online GLP-1 products are safe or equivalent to FDA-approved formulations.

What did they get wrong (or right)?

The access frustration is not wrong. GLP-1 medications have been genuinely difficult to obtain for large portions of the population, and cost remains a serious barrier. A 2023 KFF analysis found that fewer than 25% of commercially insured patients could access Wegovy without significant out-of-pocket burden. That is a real problem worth talking about.

But the #ventasonline framing appears to position an unregulated product as the answer to that problem. That is where this video goes off a cliff. Sourcing semaglutide-adjacent products through informal online channels exposes patients to real risks: incorrect dosing, contamination, and products that contain little to none of the active ingredient they claim to include. A 2024 report from the Alliance for Safe Online Pharmacies found that over 95% of online pharmacies it reviewed operated outside of legal and safety standards.

The video does not appear to give any clinical guidance, dosing information, or safety warnings. For a product associated with a medication that requires careful titration and medical supervision, that absence is a problem in itself.

What should you actually know?

If you are struggling to access semaglutide or tirzepatide through traditional channels, that is a legitimate problem with legitimate solutions that do not involve unregulated online vendors. FDA-approved compounded semaglutide from a licensed 503A or 503B compounding pharmacy is a different category from random online sellers, but even that space requires scrutiny. The FDA issued guidance in 2024 clarifying that compounded semaglutide is not equivalent to Ozempic or Wegovy, and patients should understand that distinction.

Regulated telehealth platforms can connect patients with licensed providers who can evaluate whether a GLP-1 medication is clinically appropriate and help navigate legitimate pharmacy options. That is not a plug, it is just how the medical system is supposed to work. A medication that affects appetite regulation, gastrointestinal function, and cardiovascular risk needs a real clinical evaluation first.

• GLP-1 receptor agonists are prescription medications in the United States and require a licensed provider's assessment before use.
• Purchasing prescription medications from unverified online sources is illegal and carries serious health risks.
• If you see a video combining #ozempic and #ventasonline, treat it as a red flag, not a resource.